These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 23391543)
21. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Won HH; Lee J; Park JO; Park YS; Lim HY; Kang WK; Kim JW; Lee SY; Park SH Cancer; 2012 Jun; 118(11):2828-36. PubMed ID: 22020760 [TBL] [Abstract][Full Text] [Related]
22. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Uwah AN; Ackler J; Leighton JC; Pomerantz S; Tester W Clin Colorectal Cancer; 2012 Dec; 11(4):275-9. PubMed ID: 22682776 [TBL] [Abstract][Full Text] [Related]
23. The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects? Park SB; Lin CS; Krishnan AV; Kiernan MC Cancer Chemother Pharmacol; 2011 May; 67(5):1189-90; author reply 1191-2. PubMed ID: 21327679 [No Abstract] [Full Text] [Related]
25. Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review. Pulvers JN; Marx G Asia Pac J Clin Oncol; 2017 Dec; 13(6):345-355. PubMed ID: 28653815 [TBL] [Abstract][Full Text] [Related]
26. Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. Pachman DR; Ruddy K; Sangaralingham LR; Grothey A; Shah ND; Beutler AS; Hubbard JM; Loprinzi CL J Natl Compr Canc Netw; 2015 Sep; 13(9):1097-101. PubMed ID: 26358793 [TBL] [Abstract][Full Text] [Related]
28. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. Terrazzino S; Argyriou AA; Cargnin S; Antonacopoulou AG; Briani C; Bruna J; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP; Canonico PL; Genazzani AA; Cavaletti G J Peripher Nerv Syst; 2015 Mar; 20(1):15-23. PubMed ID: 25858589 [TBL] [Abstract][Full Text] [Related]
29. Oxaliplatin induced-neuropathy in digestive tumors. Sereno M; Gutiérrez-Gutiérrez G; Gómez-Raposo C; López-Gómez M; Merino-Salvador M; Tébar FZ; Rodriguez-Antona C; Casado E Crit Rev Oncol Hematol; 2014 Jan; 89(1):166-78. PubMed ID: 24029604 [TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-induced peripheral neuropathy: the end of the beginning? Krishnan AV; Park SB J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):359. PubMed ID: 23833264 [No Abstract] [Full Text] [Related]
31. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. Ushio S; Egashira N; Sada H; Kawashiri T; Shirahama M; Masuguchi K; Oishi R Eur J Cancer; 2012 Jun; 48(9):1407-13. PubMed ID: 21907570 [TBL] [Abstract][Full Text] [Related]
32. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry. Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732 [TBL] [Abstract][Full Text] [Related]
33. [Promising effects of pregabalin in the treatment of oxaliplatin-induced sensory neuropathy in patients with colorectal carcinoma]. Nagahara H; Noda E; Maeda K; Inoue T; Hirakawa T; Hasegawa T; Shibutani M; Hirakawa K Gan To Kagaku Ryoho; 2013 Sep; 40(9):1181-3. PubMed ID: 24047775 [TBL] [Abstract][Full Text] [Related]
34. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran. Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769 [TBL] [Abstract][Full Text] [Related]
36. Sudden-onset thrombocytopenia with oxaliplatin. Dold FG; Mitchell EP Ann Intern Med; 2003 Jul; 139(2):E156. PubMed ID: 12859182 [No Abstract] [Full Text] [Related]
37. Roles of Transient Receptor Potential Ankyrin 1 in Oxaliplatin-Induced Peripheral Neuropathy. Nakagawa T; Kaneko S Biol Pharm Bull; 2017; 40(7):947-953. PubMed ID: 28674258 [TBL] [Abstract][Full Text] [Related]
38. Exploration of platinum-induced neuropathy should be based on both objective and subjective examinations. Oldenburg J; Fosså SD Acta Oncol; 2009; 48(6):804-6. PubMed ID: 19484592 [No Abstract] [Full Text] [Related]
39. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Brouwers EE; Huitema AD; Boogerd W; Beijnen JH; Schellens JH Acta Oncol; 2009; 48(6):832-41. PubMed ID: 19308757 [TBL] [Abstract][Full Text] [Related]
40. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy. Kautio AL; Haanpää M; Kautiainen H; Leminen A; Kalso E; Saarto T Anticancer Res; 2011 Oct; 31(10):3493-6. PubMed ID: 21965767 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]